
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD Inc demonstrated a significant growth trajectory in its Telehealth segment, with a 14% year-over-year increase in its active subscriber base, reaching 310,818 by the end of the third quarter of 2025. The company's total revenue rose to $60.2 million, reflecting a 12.7% increase year-over-year, largely driven by a 17.4% growth in Telehealth revenue, which reached $47.3 million. The firm has also re-established its growth momentum through strategic product offerings, such as the introduction of GLP-1 medications at competitive pricing, indicating an overall improvement in market conditions and robust demand for its telehealth services.
Bears say
LifeMD Inc. reported revenue of $60.2 million for the latest quarter, reflecting a 13% year-over-year increase, but this figure fell short of consensus expectations, indicating a slowdown in top-line growth due to reduced marketing of compounded products. The company also missed adjusted EBITDA projections, reporting $5.1 million—20% higher than the previous year—but below guidance, highlighting ongoing profitability challenges amidst competitive pressures in the telehealth sector. Additionally, LifeMD has lowered its full-year 2025 revenue guidance for the telehealth segment to between $192 million and $193 million, following increased competition from lower-cost alternatives and signaling potential operational hurdles that may adversely affect future growth and investor confidence.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares